FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

مكتبة البروتيدات

Compound FDA-Regulated

هذه المركبة مدعومة من قبل FDA أو تحت الرقابة. شراء دون وصفة طبية صالحة قد يخالف القانون الفيدرالي. تأكد من جميع المتطلبات القانونية في مجالك.

Tirzepatide

Mounjaro / Zepbound

Weight Loss & Metabolic

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly, approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It represents a significant advancement over single-agonist GLP-1 drugs like semaglutide, demonstrating superior weight loss and glycemic control in head-to-head trials. The molecule is a 39-amino acid synthetic peptide with a C20 fatty diacid moiety enabling once-weekly dosing through albumin binding.

mechanism of action

Dual GIP/GLP-1 receptor agonist. Activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors simultaneously. Produces greater weight loss and glycemic control than single-receptor agonists.

Research Protocols

للاستخدام البحثي فقط. ليس مشورة طبية.

Research protocols start at 2.5mg weekly for 4 weeks, escalating through 5mg, 7.5mg, 10mg, 12.5mg, to a maximum of 15mg weekly.

Research Notes

Clinical Research Status

Tirzepatide received FDA approval for type 2 diabetes (Mounjaro) in May 2022 and for chronic weight management (Zepbound) in November 2023. The SURMOUNT clinical program demonstrated unprecedented weight loss of up to 22.5% at the highest dose in non-diabetic obese adults. Ongoing trials are investigating applications in heart failure with preserved ejection fraction (HFpEF), obstructive sleep apnea, and MASH/NASH.

Key Published Findings

The SURPASS-2 trial showed tirzepatide 15mg was superior to semaglutide 1mg for both HbA1c reduction (-2.46% vs -1.86%) and weight loss (-12.4kg vs -6.2kg). SURMOUNT-1 demonstrated that 22.5% of participants on the 15mg dose achieved greater than 25% body weight loss at 72 weeks. The SURMOUNT-4 trial confirmed that weight regain occurs upon discontinuation, with participants regaining approximately 14% of lost weight after stopping treatment.

Safety Profile

The most common adverse events are gastrointestinal: nausea (12-33%), diarrhea (12-21%), and vomiting (5-12%), generally mild-to-moderate and decreasing with continued use. A boxed warning exists for thyroid C-cell tumors based on rodent studies, though human relevance is uncertain. Pancreatitis, gallbladder events, and hypoglycemia (when combined with sulfonylureas or insulin) are less common but clinically significant risks.

Drug Interactions & Contraindications

Tirzepatide slows gastric emptying, potentially affecting absorption of oral medications, particularly oral contraceptives (backup contraception recommended for 4 weeks after initiation or dose increase). Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Dose adjustments may be needed for insulin and sulfonylureas to prevent hypoglycemia when used in combination.

Comparison to Related Compounds

Head-to-head data from SURPASS-2 shows tirzepatide's superiority over semaglutide for both weight loss and glycemic control, likely attributable to the additive GIP receptor agonism. Unlike semaglutide which is purely a GLP-1 agonist, tirzepatide's dual mechanism may better preserve lean mass during weight loss based on preliminary body composition data. Retatrutide (Eli Lilly's triple agonist adding glucagon receptor activity) represents the next evolution, showing up to 24.2% weight loss in Phase 2 trials.

Community Observations

Available in escalating doses from 2.5mg to 15mg, with recommended titration over 20+ weeks to minimize GI side effects. Supply constraints have been a persistent issue since launch, with many patients experiencing difficulty obtaining prescriptions. Cost without insurance is approximately $1,000-1,100/month, though manufacturer savings programs and compounding pharmacies have expanded access.

Half Life

~5 days

Reconstitution

Bacteriostatic water (BAC)

Storage

Lyophilized

Room temperature up to 24 months. Protect from light.

Reconstituted

Refrigerate 2-8C. Use within 21 days.

US Legal Status

FDA-approved (Rx only)

Also Known As

MounjaroZepbound

الأسئلة الشائعة

ما هو Tirzepatide؟

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly, approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It represents a significant advancement over single-agonist GLP-1 drugs like semaglutide, demonstrating superior weight loss and glycemic control in head-to-head trials. The molecule is a 39-amino acid synthetic peptide with a C20 fatty diacid moiety enabling once-weekly dosing through albumin binding.

كيف يعمل Tirzepatide؟

Dual GIP/GLP-1 receptor agonist. Activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors simultaneously. Produces greater weight loss and glycemic control than single-receptor agonists.

ما هو الوضع التنظيمي لـ Tirzepatide في الولايات المتحدة؟

FDA-approved (Rx only)

ما هو عمر النصف لـ Tirzepatide؟

~5 days

ما الأسماء الأخرى لـ Tirzepatide؟

Mounjaro, Zepbound

Peptide Contacts provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer